UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000029469
Receipt number R000033670
Scientific Title A Phase I/II clinical trial of Carbon-ion radiotherapy in 4 fractions over 1 week for patients with renal cell carcinoma
Date of disclosure of the study information 2017/10/10
Last modified on 2024/03/05 14:12:05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Phase I/II clinical trial of Carbon-ion radiotherapy in 4 fractions over 1 week for patients with renal cell carcinoma

Acronym

Carbon-ion radiotherapy in 4 fractions for patients with renal cell carcinoma

Scientific Title

A Phase I/II clinical trial of Carbon-ion radiotherapy in 4 fractions over 1 week for patients with renal cell carcinoma

Scientific Title:Acronym

Carbon-ion radiotherapy in 4 fractions for patients with renal cell carcinoma

Region

Japan


Condition

Condition

Renal cell carcinoma

Classification by specialty

Nephrology Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the safety and efficacy of carbon-ion radiotherapy in 4 fractionsfor patients with renal cell carcinoma

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Phase I,II


Assessment

Primary outcomes

Acute adverse effect (within 90 days)

Key secondary outcomes

late adverse effect, local control, cancer specific survival, overall survival, QOL


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

Carbon-ion radiotherapy 55.2 Gy (RBE) in 4 fractions within 1 week, increased to 60.0Gy(RBE)from 6th case.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) biopsy-proven, or imaging diagnosed renal cell carcinoma
2) historogy: clear cell carcinoma, chromophobe cell carcinoma, or papillary renal cell carcinoma
3) untreated T1/T2, or T3/T4 without tumor emboli. In addition, N1M1 case with long term prognosis (according to TNM classification 2016).
4) an age >= 20
5) Performance Status (ECOG): 0-1
6)documented informed consent

Key exclusion criteria

1)target area that had been treated by other radiation therapy
2) After the start of molecular targetting therapy
3) irradiated dose to gastrointestinal tract is more than 60% of prescribed dose
4) maximum tumor diameter > 15cm
5) dialyzed RCC
6) presence of active double cancers other than RCC
7) serious medical or psychological condition precluding the safe administration of the treatment

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Hitoshi
Middle name
Last name Ishikawa

Organization

National Institutes for Quantum Science and Technology

Division name

QST hospital

Zip code

263-8555

Address

4-9-1 Anagawa, Inage Ward, Chiba-City, Japan

TEL

09097858517

Email

gokasuya@gmail.com


Public contact

Name of contact person

1st name Goro
Middle name
Last name Kasuya

Organization

National Institutes for Quantum Science and Technology

Division name

QST hospital

Zip code

263-8555

Address

4-9-1 Anagawa, Inage Ward, Chiba-City, Japan

TEL

043-206-3360

Homepage URL


Email

kasuya.goro@qst.go.jp


Sponsor or person

Institute

National Institutes for Quantum Science and Technology

Institute

Department

Personal name



Funding Source

Organization

Ministry of Education, Culture, Sports, Science and Technology

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Institutes for Quantum Science and Technology Certified Review Board

Address

4-9-1 Anag awa, Inage-ku, Chiba-shi, Chiba

Tel

0 4 3 -2 0 6 -4 7 0 6

Email

helsinki@ q s t.g o .jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 10 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

10

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 10 Month 04 Day

Date of IRB

2019 Year 09 Month 17 Day

Anticipated trial start date

2017 Year 10 Month 10 Day

Last follow-up date

2023 Year 10 Month 17 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 10 Month 08 Day

Last modified on

2024 Year 03 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033670


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name